Avadel, Lumryz
Avadel Gets Expanded FDA OK of Lumryz for Use in Children
Avadel Pharmaceuticals has won expanded Food and Drug Administration approval of its narcolepsy drug Lumryz for use in children. Avadel on Thursday said the FDA nod covers Lumryz for the treatment of cataplexy, or excessive daytime sleepiness, in children ages seven and older with narcolepsy, a chronic sleep disorder.
Avadel's drug contains a central nervous system depressant drug called sodium oxybate, which helps increase the amount of ...
The U.S. Food and Drug Administration has approved Avadel Pharmaceuticals' sleep disorder drug for children aged 7 years and ...
Shares of Jazz Pharmaceuticals are trading only slightly higher in the last few weeks despite two unexpected wins. Explore ...
A summary of recent health news updates reveals declining Marburg cases in Rwanda, Texas suing a doctor over prescribing ...
(RTTNews) - Avadel Pharmaceuticals plc (AVDL), Tuesday revealed that 94 percent of patients in RESTORE study with narcolepsy preferred the once-nightly regimen of Lumryz over twice-nightly Oxybate ...
This ruling removed a major risk that could have prevented Avadel from marketing its LUMRYZ product for narcolepsy. Livnat also sees the block on Avadel’s approval for an idiopathic hypersomnia ...
Post-hoc analysis from pivotal Phase 3 REST-ON trial confirmed the efficacy of LUMRYZ in study participants who were and were not using a stable dose of an alerting agent – – Baseline data ...
DUBLIN - Avadel Pharmaceuticals plc (NASDAQ:AVDL) released final data from their RESTORE study, indicating a strong preference for their once-nightly narcolepsy medication, LUMRYZ, over traditional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback